Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The NCI seeks research co-development partners or licensees for NPM1 Mutation-Specific T Cell Receptors for Targeted Treatment of AML.
The NCI seeks research co-development partners or licensees for NPM1 Mutation-Specific T Cell Receptors for Targeted Treatment of AML.
FOR FURTHER INFORMATION CONTACT:
Inquiries related to this license opportunity should be directed to: Abritee Dhal, Ph.D., Technology Transfer Manager, NCI, Technology Transfer Center, Email:
abritee.dhal@nih.gov
or Phone: 240-276-6154.
SUPPLEMENTARY INFORMATION:
AML is a rare form of blood cancer affecting myeloid stem and progenitor cells, associated with a poor prognosis and a 5-year survival rate of ~33%. Current treatments, including intensive chemotherapy and stem cell transplantation, are not suitable for all patients and can cause significant toxicities, including low blood cell counts, infection and graft-versus-host disease. Therefore, there is a need for safer and more effective treatments.
This specific invention concerns the isolation of two highly specific T cell receptors (TCRs), known as TCR6 and TCR7, recognizing a neoepitope, AVEEVSLRK. The neoepitope is derived from mutant NPM1 and presented in the context of HLA-A*11:01. Pre-clinical results for these TCRs revealed robust and specific cytotoxicity against a leukemia cell line and several patient-derived AML samples expressing the NPM1 mutation and HLA-A*11:01. Furthermore, they showed no cross-reactivity to normal peripheral blood mononuclear cells, structurally similar peptides or unrelated HLA alleles. These results suggest these novel TCRs represent a potential adoptive T cell therapy for the treatment of AML.
“This Notice is in accordance with 37 CFR 404.4 Authority to grant licenses.”
NIH Reference Number:
E-200-2025-0.
Related Technologies:
N/A.
Product Type:
Therapeutic.
Therapeutic Area(s):
Oncology.
Development Stage:
Pre-clinical (
in vivo
validation).
Minimal off-target effects with enhanced safety profile.
Significant unmet medical need for AML patients.
Collaboration Opportunity:
Researchers at the NCI seek licensing and/or co-development research collaborations for NPM1 Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.
Dated: July 21, 2026.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer Institute.